Cardiorenal Syndrome Market

• The cardiorenal syndrome market is projected to grow steadily during the forecast period (2025–2034), driven by emerging therapies, advanced diagnostics, rising disease awareness, and an increasing number of reported cases, creating a promising and evolving market landscape.
• The rising cases of cardiorenal syndrome are mainly due to the growing burden of diabetes, hypertension, and heart failure—fueling a vicious cycle between the heart and kidneys. As these chronic conditions become more prevalent with aging populations and lifestyle-related risk factors, the delicate balance between cardiac and renal function is increasingly disrupted. This dual-organ dysfunction not only complicates treatment but also significantly worsens patient outcomes.
• Cardiorenal syndrome management requires timely, severity-based intervention. Mild cases may respond to oral diuretics and neurohormonal agents, while advanced cases often necessitate IV diuretics, inotropes, or renal replacement therapy. Treatment is guided by hemodynamic status, biomarkers, and organ function. Poor response indicates potential progression or treatment resistance, warranting escalation of care.
• The treatment landscape for cardiorenal syndrome is evolving with therapies that address both cardiac and renal complications. Notable approved options include OZEMPIC (semaglutide), KERENDIA (finerenone), and FARXIGA (dapagliflozin), among others.
• Despite advances in heart failure and chronic kidney disease (CKD) management, cardiorenal syndrome continues to face key unmet needs due to the lack of therapies that effectively address both cardiac and renal dysfunction simultaneously. Current treatment options are often suboptimal, with limited data on their impact across dual-organ failure, and the absence of standardized treatment protocols further complicates care.
• The emerging pipeline for cardiorenal syndrome includes promising candidates such as PolyCore (Polydextrin, L-Carnitine, D-xylitol) and balcinrenone/dapagliflozin combination, among others. These investigational therapies aim to address existing treatment gaps and offer novel approaches in this clinically complex and underserved area.
• A major unmet need in the cardiorenal syndrome market is the absence of targeted therapies that simultaneously address the intertwined pathophysiology of cardiac and renal dysfunction, limiting effective disease modification and long-term outcomes.
• AstraZeneca is expected to release Phase III BalanceD-HF trial results for the balcinrenone/dapagliflozin combination after 2026. This combination, targeting heart failure, could potentially expand AstraZeneca’s footprint in the cardio-renal-metabolic space if the data proves favorable

Factors affecting Cardiorenal Syndrome Market Growth

• Rising Prevalence of Cardiovascular and Renal Disorders

The growing incidence of heart failure, chronic kidney disease (CKD), hypertension, and diabetes contributes directly to the prevalence of cardiorenal syndrome. As these conditions increase globally, demand for effective CRS management rises.

• Advancements in Diagnostic and Monitoring Tools

Innovations in biomarkers, imaging techniques, and renal-cardiac monitoring systems enable early detection and better management of CRS. Improved diagnostics enhance treatment outcomes and drive adoption of therapies.

• Unmet Medical Need and Complexity of CRS Management

Cardiorenal syndrome is challenging to treat due to the interplay between heart and kidney dysfunction. This unmet need fosters research and adoption of novel therapeutic strategies, including pharmacologic and device-based interventions.

• Rising Awareness Among Healthcare Professionals and Patients

Increased awareness about the risks, early signs, and complications of CRS promotes timely diagnosis and treatment, expanding the market.

• Technological Innovations in Therapeutics

Development of novel drugs such as SGLT2 inhibitors, RAAS modulators, and diuretics, as well as combination therapies, improves patient outcomes and drives market growth.

• Increasing Healthcare Expenditure and Infrastructure

Improved healthcare systems, specialized cardio-renal care units, and investment in advanced therapies contribute to greater accessibility and uptake of CRS treatments.

• Growing Focus on Personalized Medicine

Tailoring treatment to individual patient profiles, considering both cardiac and renal function, enhances therapeutic efficacy and encourages the adoption of advanced treatment options.

DelveInsight’s comprehensive report titled “Cardiorenal Syndrome — Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of Cardiorenal Syndrome. The report presents historical and projected epidemiological data covering total prevalent cases of selected indications for cardiorenal syndrome, total diagnosed prevalent cases of selected indications for cardiorenal syndrome, total diagnosed prevalent cases of cardiorenal syndrome, and treated cases of cardiorenal syndrome. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in cardiorenal syndrome. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Cardiorenal Syndrome Overview

Cardiorenal syndrome is a multifactorial disorder characterized by bidirectional organ dysfunction, where impairment in cardiac or renal function leads to secondary dysfunction in the other organ. It involves complex interrelated mechanisms including neurohormonal activation, altered hemodynamics, endothelial dysfunction, and systemic inflammation. Cardiorenal syndrome can develop acutely or chronically and is commonly associated with conditions such as heart failure, CKD, hypertension, and diabetes. Its progression underscores the need for integrated, multidisciplinary management approaches.

Cardiorenal syndrome may include fatigue, dyspnea, reduced urine output, peripheral and abdominal edema, cognitive disturbances, and arrhythmic sensations such as palpitations. These symptoms reflect the underlying hemodynamic and metabolic disturbances resulting from combined cardiac and renal dysfunction, and their presence often indicates disease progression and the need for comprehensive clinical evaluation.

Cardiorenal Syndrome Diagnosis and Treatment Algorithm 

There is no definitive test for diagnosing cardiorenal syndrome. Diagnosis is based on clinical judgment through careful evaluation of fluid status and organ function. It requires correlating multiple clinical parameters to differentiate cardiorenal syndrome from isolated cardiac or renal conditions, emphasizing the importance of a comprehensive and integrative approach.

The primary goal of treating cardiorenal syndrome is to restore and maintain optimal fluid and hemodynamic balance, which becomes challenging due to the interdependent dysfunction of the heart and kidneys. Management involves a combination of pharmacologic and device-based therapies tailored to individual needs. Common treatments include diuretics, beta-blockers, ACE inhibitors, ARBs, ARNI, mineralocorticoid receptor antagonists, renin-angiotensin system blockers, and inotropes. In advanced cases, interventions such as ultrafiltration, dialysis, implantable devices (ICD, LVAD, CRT), or organ transplantation (heart or kidney) may be required to stabilize function and improve outcomes.

Cardiorenal Syndrome Epidemiology

The epidemiology section of the cardiorenal syndrome market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Cardiorenal Syndrome. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings from Cardiorenal Syndrome Epidemiological Analyses and Forecast

The American Heart Association (AHA) estimates in its Statistical Update that heart failure impacts around 1.8% of the overall US population.

In the US, over 1 in 10 Americans have diabetes, with type 2 diabetes comprising approximately 90–95% of all cases.

It was found that more than 1 in 7 adults in the US are living with CKD.

In the US, the prevalence of CKD among individuals with heart failure is approximately 27.7%.

In patients with diabetes mellitus, the prevalence of heart failure ranges from 9–22%—approximately four times higher than in the general population in the US—and is notably higher among those aged 60 years and older.

In the US, approximately 37% of individuals with type 2 diabetes are estimated to have CKD, highlighting a significant comorbidity burden in this population.

In the US, hypertension is highly prevalent among patients with CKD, with estimates ranging from 60–90%.

In Spain, the estimated prevalence of CKD in patients with type 2 diabetes mellitus was 27.9%.

In Japan, the prevalence of heart failure was reported to be 2.2–3.7% among patients aged 74 years or younger.

In Japan, CKD has been found to affect approximately 13% of the population.

The epidemiology of cardiorenal syndrome is expected to change during the forecast period (2025-2034).

Cardiorenal Syndrome Market Outlook

The cardiorenal syndrome therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025–2034).

LY3437943, a biologic triagonist developed by Eli Lilly, targets the GIP, GLP-1, and glucagon receptors. It is currently being investigated for its potential to reduce cardiovascular and renal complications in patients with obesity. 

http://lilly.com/science/research-development/pipeline 

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the cardiorenal syndrome market in the 7MM is expected to change significantly during the study period 2020–2034.

Cardiorenal Syndrome Drug Chapters 

Marketed Cardiorenal Syndrome Drugs

• KERENDIA (finerenone): Bayer

KERENDIA, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA) developed by Bayer HealthCare Pharmaceuticals, selectively targets mineralocorticoid receptor overactivation in the heart and kidneys, mitigating inflammation and fibrosis in chronic conditions. 

Approved in the US, EU, and Japan, KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and heart failure hospitalization in adults with CKD associated with T2DM. It also lowers the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure and LVEF ≥ 40%.

• OZEMPIC (semaglutide): Novo Nordisk

OZEMPIC is a GLP-1 receptor agonist approved in the US, EU, and Japan for the management of type 2 diabetes. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease. 

Additionally, OZEMPIC slows the progression of kidney disease, helping lower the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD.

• FARXIGA/FORXIGA (dapagliflozin): AstraZeneca

Dapagliflozinis a first-in-class, oral SGLT2 inhibitor approved for treating type 2 diabetes, heart failure (HFrEF and HFpEF), and CKD. It offers broad cardiorenal protection by targeting the interlinked functions of the heart, kidneys, and pancreas.

Approved in the US, EU, and Japan, dapagliflozin is indicated to treat heart failure across all ejection fractions, chronic kidney disease (with or without type 2 diabetes), and to improve glycemic control in adults and children (≥10 years) with type 2 diabetes, while reducing risks of CV death, HF hospitalization, and renal decline.

In February 2014, AstraZeneca acquired full ownership of Bristol-Myers Squibb’s stake in their diabetes alliance, including rights to dapagliflozin. 

Note: Detailed marketed therapies assessment will be provided in the final report.

Emerging Cardiorenal Syndrome Drugs 

The cardiorenal syndrome market is expected to evolve gradually with the introduction of emerging therapies. Key players such as AstraZeneca and Iperboreal Pharma, among others, have shown strong interest in this space and are actively developing potential treatments to address the unmet needs of this complex condition.

• Balcinrenone/dapagliflozin: AstraZeneca

Balcinrenone/dapagliflozin is an investigational oral small-molecule combination therapy that pairs a mineralocorticoid receptor (MR) modulator with an SGLT2 inhibitor. This dual mechanism is being evaluated for its potential to improve outcomes in patients with heart failure and coexisting CKD.

The drug is currently being evaluated in the Phase III BalanceD-HF trial in patients with patients with heart failure and impaired kidney function.

• PolyCore (Polydextrin, L-Carnitine, D-xylitol): Iperboreal Pharma

PolyCore is an innovative osmo-metabolic and colloidal-based ultrafiltration solution designed for continuous ambulatory peritoneal dialysis (CAPD). Engineered for high biocompatibility, it minimizes intra-peritoneal glucose exposure while incorporating bioactive agents that help preserve peritoneal membrane integrity, supporting sustained therapy and long-term patient benefit. 

By enabling efficient and durable fluid removal through peritoneal ultrafiltration, PolyCore addresses a critical need in managing fluid overload in cardio-renal syndrome. It is currently being evaluated in a Phase I/II trial for its potential to prevent heart failure exacerbation in this high-risk population.

Note: Detailed emerging therapies assessment will be provided in the final report.

Cardiorenal Syndrome Market Segmentation

DelveInsight’s ‘Cardiorenal Syndrome – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future cardiorenal syndrome market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Cardiorenal Syndrome Market Size by Countries

The cardiorenal syndrome market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) cardiorenal syndrome market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Cardiorenal Syndrome Market Size by Therapies

Cardiorenal Syndrome Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034. 

Note: Detailed market segment assessment will be provided in the final report.

Cardiorenal Syndrome Drugs Uptake

This section focuses on the sales uptake of potential cardiorenal syndrome drugs that have recently been launched or are anticipated to be launched in the cardiorenal syndrome market between 2020 and 2034. It estimates the market penetration of cardiorenal syndrome drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the cardiorenal syndrome market.

The emerging cardiorenal syndrome therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the cardiorenal syndrome market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Cardiorenal Syndrome.

Cardiorenal Syndrome Market Access and Reimbursement

DelveInsight’s ‘Cardiorenal Syndrome – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of cardiorenal syndrome.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

Latest KOL Views on Cardiorenal Syndrome Market

To keep up with current cardiorenal syndrome market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the cardiorenal syndrome domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or cardiorenal syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the cardiorenal syndrome unmet needs.

Cardiorenal Syndrome: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the University of California, US; University of Pennsylvania, US; University Hospital Heidelberg, Germany; San Raffaele Scientific Institute, Italy; San Raffaele Scientific Institute, Italy; Hospital Universitario Vall d'Hebron, Spain; University of Tokyo Hospital, Japan, and others.

“Cardiorenal syndrome diagnosis demands an integrated approach using biomarkers (creatinine, GFR, BNP, troponins), albumin-to-creatinine ratio, and imaging (echo, MRI, CT) to assess cardiorenal function and hemodynamics. Precise subtype identification is key for optimizing therapy and prognosis.”

“Managing CRS remains challenging due to the intricacies of concurrent heart and kidney dysfunction, which require coordinated cardiology-nephrology care. The lack of specialized cardiorenal units, standardized protocols, and trained teams limits effective intervention, especially in critical care. Integrated care models and system-level strategies are crucial to improving outcomes.”

“Cardiorenal syndrome treatment requires a tailored mix of pharmacologic and lifestyle interventions based on subtype and severity. Core therapies include diuretics, ACE inhibitors/ARBs, beta-blockers, and anticoagulants, alongside sodium restriction and risk factor control. Emerging options like SGLT2 inhibitors and sacubitril-valsartan show promise in improving outcomes without renal compromise. Specialized cardiorenal units enhance treatment precision and reduce mortality and rehospitalization.”

Note: Detailed assessment of KOL Views will be provided in the full report on Cardiorenal Syndrome.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the cardiorenal syndrome Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Cardiorenal Syndrome Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase I, Phase II and Phase III stages and examines companies involved in developing targeted therapeutics for Cardiorenal Syndrome. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging cardiorenal syndrome therapies.

Cardiorenal Syndrome Report Insights

• Cardiorenal Syndrome Patient Population
• Therapeutic Approaches
• Cardiorenal Syndrome Pipeline Analysis
• Cardiorenal Syndrome Market Size and Trends
• Cardiorenal Syndrome Market Opportunities
• Impact of Upcoming Therapies

Cardiorenal Syndrome Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Cardiorenal Syndrome Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Cardiorenal Syndrome Market
• Cardiorenal Syndrome Drugs Uptake

Cardiorenal Syndrome Report Assessment

• Cardiorenal Syndrome Current Treatment Practices
• Unmet Needs
• Cardiorenal Syndrome Pipeline Product Profiles
• Cardiorenal Syndrome Market Attractiveness

Key Questions Answered in the Cardiorenal Syndrome Report

• How common is cardiorenal syndrome?
• What are the key findings of cardiorenal syndrome epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for cardiorenal syndrome?
• What are the disease risk, burden, and unmet needs of cardiorenal syndrome?
• At what CAGR is the cardiorenal syndrome market and its epidemiology is expected to grow in the 7MM during the forecast period (2025–2034)?
• How would the unmet needs impact the cardiorenal syndrome market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of cardiorenal syndrome in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025–2034)?
• How many companies are currently developing therapies for the treatment of cardiorenal syndrome?

Reasons to buy the Cardiorenal Syndrome Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the cardiorenal syndrome market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.